Acetyl-L-carnitine in Combination With a Cisplatin-containing Chemotherapy as First Line Treatment of Advanced or Metastatic Non Small Cell Lung Cancer

This study has been terminated.
(Recruitment was prematurely stopped due to difficulty of recruitment encountered by the experimental centers)
Sponsor:
Information provided by (Responsible Party):
Mario Negri Institute for Pharmacological Research
ClinicalTrials.gov Identifier:
NCT01379976
First received: June 16, 2011
Last updated: July 31, 2014
Last verified: July 2014

June 16, 2011
July 31, 2014
April 2011
October 2014   (final data collection date for primary outcome measure)
Toxicity Free Survival [ Time Frame: participants will be followed for the duration of chemotherapy and for at least 1 yaer after the completation of treatment, an expected average of 18 months ] [ Designated as safety issue: Yes ]
The primary efficacy endpoint is toxicity-free survival, defined as the time from randomisation up to the occurrence of related to treatment grade 2-3-4 NCI-CTCAE neurotoxicity, progression, second primary malignancy, death from any cause, whichever comes first. Subjects who have not experienced related to treatment grade 2-3-4 toxicity, and not progressed or died while on study will be censored at their last assessment date.
Same as current
Complete list of historical versions of study NCT01379976 on ClinicalTrials.gov Archive Site
  • Progression-free survival [ Time Frame: participants will be followed for the duration of chemotherapy and for at least 1 yaer after the completation of treatment, an expected average of 18 months ] [ Designated as safety issue: No ]
    defined as the time from randomisation up to the occurrence of progression, second primary malignancy, death from any cause, whichever comes first. Subjects who have not progressed or died while on study will be censored at their last assessment date
  • Overall survival [ Time Frame: participants will be followed for the duration of chemotherapy and for at least 1 yaer after the completation of treatment, an expected average of 18 months ] [ Designated as safety issue: No ]
    defined as the time from the date of randomisation to the date of death from any cause. Subjects not reported as having died at the end of the study will be censored at the date they were last known to be alive
  • Neuropathic pain [ Time Frame: participants will be followed for the duration of chemotherapy and for at least 1 yaer after the completation of treatment, an expected average of 18 months ] [ Designated as safety issue: No ]
    Occurrence of neuropathic pain is defined as the presence of at least 4 of the 10 clinical signs/symptoms listed in the DN4-Questionnaire Neuropathic pain intensity is defined as the intensity of pain reported by patients (current, average and worst during the last week) during scheduled visit as assessed by a self-administered questionnaire (BPI)
Same as current
Not Provided
Not Provided
 
Acetyl-L-carnitine in Combination With a Cisplatin-containing Chemotherapy as First Line Treatment of Advanced or Metastatic Non Small Cell Lung Cancer
Randomized, Double-blind, Placebo-controlled Phase 3 Trial to Assess the Efficacy and Safety of Acetyl-L-carnitine in Combination With a Cisplatin-containing Chemotherapy as First Line Treatment of Advanced or Metastatic Non Small Cell Lung Cancer

Study objectives Primary: To compare toxicity free survival of patients treated with ALC (acetylcarnitine) plus cisplatin-containing chemotherapy (CHT) versus those treated with placebo plus cisplatin-containing chemotherapy.

Secondary: To compare progression free survival, overall survival, the compliance to treatment, the number of episodes of grade 3-4 National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0, neurotoxicity, as well as the proportion of patients experiencing grade 2-3-4 National Cancer Institute Common Terminology Criteria for Adverse Events, neuropathic pain intensity, the clinical signs and/or symptoms (such as burning, numbness, itching, etc.) of the sensorial neuropathy between the two treatment arms. Study design Multicentre, randomised, double-blind, placebo-controlled, phase III, superiority study in patients with advanced or metastatic NSCLC (non small cell lung cancer).

Patients to be screened for study inclusion are those for which the decision to start a cisplatin-containing treatment has been already taken in the context of the clinical practice. The type of cisplatin-based treatment is not fixed, but each single investigator is free to choose for each single patient among those already approved for first line treatment of advanced or metastatic NSCLC.

Patients meeting the eligibility criteria will be randomized with a 1 : 1 ratio to receive ALC + cisplatin-containing CHT or Placebo + cisplatin-containing CHT until patient refusal, disease progression, unacceptable toxicity or death. The study will be conducted in Italy in approximately 20 investigational centers in order to recruit 650-675 subjects over a 30-month period.

Both efficacy and safety data will be collected. Follow-up will be according to the clinical practice. Data capture will continue, for each patient, until death or study closure.

Inclusion criteria:

  • Male or female >= 18
  • No previous CHT or targeted therapies. Previous adjuvant or neo-adjuvant treatment is permitted if completed ≥ 6 months before study inclusion.
  • ECOG performance status 0-1
  • Adequate organ functions defined as follows:
  • Neutrophils >= 1.5 x 109/L, platelets >= 100 x 109/L, and hemoglobin >= 9 g/dL
  • Bilirubin level either normal or < 1.5 x ULN
  • ASAT and ALAT <= 2.5 x ULN (<= 5 x ULN if liver metastasis are present)
  • Serum creatinine <1.5 x ULN
  • Written informed consent given before the randomization, according to International Conference on Harmonization/Good Clinical Practice (ICH/GCP)

Exclusion criteria:

  • Symptomatic brain metastases
  • Any investigational agent(s) within 4 weeks prior to study entry
  • Clinically relevant coronary artery disease or a history of a myocardial infarction within the last 12 months
  • Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease
  • Patients with known allergy to any other components of the study drugs
  • History or presence of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or patient at high risk from treatment complication
  • Known drug abuse/ alcohol abuse
  • Legal incapacity or limited legal capacity
  • Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent
  • Clinically relevant peripheral neuropathy
  • Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of the cervix (Patients with a previous malignancy but without evidence of disease for 5 years will be allowed to enter the trial)
  • Pregnancy or breast feeding. Women of childbearing potential and their parents must be willing to practice acceptable methods of birth control to prevent pregnancy
  • Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Non Small Cell Lung Cancer
  • Drug: Acetylcarnitine

    ALC or placebo will be administered concurrently with CHT at 1000 mg sachet three times every day (before meals).

    Treatment should be administered for a maximum of 6 cycles for both arms unless progression or unacceptable toxicity, or treatment refusal.

    Other Name: ST 200
  • Drug: Placebo

    ALC or placebo will be administered concurrently with CHT at 1000 mg sachet three times every day (before meals).

    Treatment should be administered for a maximum of 6 cycles for both arms unless progression or unacceptable toxicity, or treatment refusal.

  • Placebo Comparator: CHT cisplatin containing + placebo
    Intervention: Drug: Placebo
  • Experimental: CHT cisplatin containing + acetyl-L-carnitina
    Intervention: Drug: Acetylcarnitine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
675
October 2014
October 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female ≥ 18
  • No previous CHT or targeted therapies. Previous adjuvant or neo-adjuvant treatment is permitted if completed ≥ 6 months before study inclusion.
  • ECOG performance status 0-1
  • Adequate organ functions defined as follows:
  • Neutrophils ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, and hemoglobin ≥ 9 g/dL
  • Bilirubin level either normal or < 1.5 x ULN
  • ASAT and ALAT < 2.5 x ULN (< 5 x ULN if liver metastasis are present)
  • Serum creatinine <1.5 x ULN
  • Written informed consent given before the randomization, according to International Conference on Harmonization/Good Clinical Practice (ICH/GCP)

Exclusion Criteria:

  • Symptomatic brain metastases
  • Any investigational agent(s) within 4 weeks prior to study entry
  • Clinically relevant coronary artery disease or a history of a myocardial infarction within the last 12 months
  • Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease
  • Patients with known allergy to any other components of the study drugs
  • History or presence of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or patient at high risk from treatment complication
  • Known drug abuse/ alcohol abuse
  • Legal incapacity or limited legal capacity
  • Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent
  • Clinically relevant peripheral neuropathy
  • Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of the cervix (Patients with a previous malignancy but without evidence of disease for < 5 years will be allowed to enter the trial)
  • Pregnancy or breast feeding. Women of childbearing potential and their parents must be willing to practice acceptable methods of birth control to prevent pregnancy
  • Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Italy
 
NCT01379976
2010-022021-15
Yes
Mario Negri Institute for Pharmacological Research
Mario Negri Institute for Pharmacological Research
Not Provided
Principal Investigator: Lucio Crinò, MD Azienda Ospedaliera di Perugia
Mario Negri Institute for Pharmacological Research
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP